Lenalidomide: an emerging option in chronic lymphocytic leukemia


https://doi.org/10.4081/hmr.v3i3.582
Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
Published: June 12, 2009
Abstract Views: 156
PDF: 182
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Lenalidomide is a thalidomidederivative that has shown clinical activity in multiple myeloma, myelodysplastic syndrome (del5q syndrome) and non-Hodgkin’s lymphomas. It belongs to a class of agents called immunomodulating drugs (IMiDs). In comparison to thalidomide, it is a more potent inhibitor of tumor necrosis factor alpha (TNF-a), while retaining some of its anti-angiogenic properties. Our group became interested in evaluating the therapeutic potential of lenalidomide in chronic lymphocytic leukemia (CLL) while searching for TNF-a and VEGF inhibitors. The rationale for targeting TNF-a and VEGF in CLL is based on our observation that patients with CLL have higher levels of TNF-a and VEGF-R2 than normal subjects and that high levels of these cytokines are associated with more aggressive disease and an inferior outcome.1,2

Supporting Agencies


Ferrajoli, A., O’Brien, S., O’Brien, S., Faderl1, S., Faderl1, S., Wierda, W., Wierda, W., Reuben, J., Reuben, J., Keating, M., & Keating, M. (2009). Lenalidomide: an emerging option in chronic lymphocytic leukemia. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.582
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC